WO2007054725A3 - Produit compose - Google Patents

Produit compose Download PDF

Info

Publication number
WO2007054725A3
WO2007054725A3 PCT/GB2006/004224 GB2006004224W WO2007054725A3 WO 2007054725 A3 WO2007054725 A3 WO 2007054725A3 GB 2006004224 W GB2006004224 W GB 2006004224W WO 2007054725 A3 WO2007054725 A3 WO 2007054725A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
hdac inhibitor
combination
hdac
compound
Prior art date
Application number
PCT/GB2006/004224
Other languages
English (en)
Other versions
WO2007054725A2 (fr
Inventor
Simon Green
Sheelagh Frame
Ian Fleming
Original Assignee
Cyclacel Ltd
Simon Green
Sheelagh Frame
Ian Fleming
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0523040.4A external-priority patent/GB0523040D0/en
Priority claimed from GB0523160A external-priority patent/GB0523160D0/en
Application filed by Cyclacel Ltd, Simon Green, Sheelagh Frame, Ian Fleming filed Critical Cyclacel Ltd
Priority to EP06808516A priority Critical patent/EP1951307A2/fr
Publication of WO2007054725A2 publication Critical patent/WO2007054725A2/fr
Publication of WO2007054725A3 publication Critical patent/WO2007054725A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne, selon un premier aspect, un produit composé comprenant un inhibiteur de HDAC et un composé représenté par la formule (I) ou (II), ou un sel pharmaceutiquement acceptable de celui-ci, et un inhibiteur de HDAC. Cette invention concerne, selon un deuxième aspect, un produit pharmaceutique comprenant un inhibiteur de HDAC et un composé représenté par la formule (I) ou (II), ou un sel pharmaceutiquement acceptable de celui-ci, comme préparation combinée destinée à être utilisée de manière simultanée, séquentielle ou séparée en thérapie. Cette invention concerne, selon un troisième aspect, une méthode de traitement d'un trouble proliférant, laquelle méthode consiste à administrer simultanément, séquentiellement ou séparément un composé représenté par la formule (I) ou (II), ou un sel pharmaceutiquement acceptable de celui-ci, et un inhibiteur de HDAC à un sujet.
PCT/GB2006/004224 2005-11-11 2006-11-13 Produit compose WO2007054725A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06808516A EP1951307A2 (fr) 2005-11-11 2006-11-13 Combinaison d'un inhibiteur cdk avec un inhibiteur d'hdac

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0523040.4A GB0523040D0 (en) 2005-11-11 2005-11-11 Combination
GB0523040.4 2005-11-11
GB0523160A GB0523160D0 (en) 2005-11-14 2005-11-14 Combination
GB0523160.0 2005-11-14

Publications (2)

Publication Number Publication Date
WO2007054725A2 WO2007054725A2 (fr) 2007-05-18
WO2007054725A3 true WO2007054725A3 (fr) 2007-08-09

Family

ID=37603117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/004224 WO2007054725A2 (fr) 2005-11-11 2006-11-13 Produit compose

Country Status (2)

Country Link
EP (1) EP1951307A2 (fr)
WO (1) WO2007054725A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636298B2 (en) * 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
EP3957637B1 (fr) * 2015-08-04 2023-06-28 Aucentra Therapeutics Pty Ltd Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidine-2-amine utilisés comme composés thérapeutiques
EP4114375A4 (fr) * 2020-03-02 2024-05-29 Sironax Ltd Inhibiteurs de ferroptose-diarylamine para-acétamides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016612A2 (fr) * 2002-08-15 2004-02-26 Cyclacel Limited Nouveaux derives puriques
US20050004007A1 (en) * 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
WO2005012298A1 (fr) * 2003-07-30 2005-02-10 Cyclacel Limited Derives de pyridinylamino-pyrimidine utiles comme inhibiteurs de la proteine kinase
WO2005042525A1 (fr) * 2003-10-21 2005-05-12 Cyclacel Limited Composes de pyrimidin-4-yl-3, 4-thione et leur utilisation a des fins therapeutiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004007A1 (en) * 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
WO2004016612A2 (fr) * 2002-08-15 2004-02-26 Cyclacel Limited Nouveaux derives puriques
WO2005012298A1 (fr) * 2003-07-30 2005-02-10 Cyclacel Limited Derives de pyridinylamino-pyrimidine utiles comme inhibiteurs de la proteine kinase
WO2005042525A1 (fr) * 2003-10-21 2005-05-12 Cyclacel Limited Composes de pyrimidin-4-yl-3, 4-thione et leur utilisation a des fins therapeutiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIBLE K C ET AL: "FLAVOPIRIDOL: a CYTOTOXIC FLAVONE THAT INDUCES CELL DEATH IN NONCYCLING A549 HUMAN LUNG CARCINOMA CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, 1 November 1996 (1996-11-01), pages 4856 - 4861, XP002125982, ISSN: 0008-5472 *
REID TONY ET AL: "Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.", LUNG CANCER (AMSTERDAM, NETHERLANDS) SEP 2004, vol. 45, no. 3, September 2004 (2004-09-01), pages 381 - 386, XP002415089, ISSN: 0169-5002 *
ROSATO ROBERTO R ET AL: "Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.", MOLECULAR PHARMACOLOGY, vol. 65, no. 3, March 2004 (2004-03-01), pages 571 - 581, XP002415088, ISSN: 0026-895X *
SHABBEER S ET AL: "FOCUS ON DEACETYLATION FOR THERAPEUTIC BENEFIT", IDRUGS, CURRENT DRUGS LTD, GB, vol. 8, no. 2, 2 February 2005 (2005-02-02), pages 144 - 154, XP009066252, ISSN: 1369-7056 *

Also Published As

Publication number Publication date
EP1951307A2 (fr) 2008-08-06
WO2007054725A2 (fr) 2007-05-18

Similar Documents

Publication Publication Date Title
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
NO20084256L (no) DPP IV inhibitorformuleringer
IL220480A0 (en) 1-benzyl-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors , preparation method thereof, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
WO2007075554A3 (fr) Traitement combine avec une composition d’inhibiteur de proteine kinase heterobicyclique a noyau 6,6-bicyclique et d'agents anticancereux
WO2009071480A3 (fr) Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase
IL221795B (en) Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates
WO2009121872A3 (fr) Tétrahydroisoquinoléines, compositions pharmaceutiques les contenant et leur utilisation en thérapie
WO2007022408A3 (fr) Methodes de traitement du cancer combinant saha et targretin
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
TW200612922A (en) Inhibitors of hsp90
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2005074989A3 (fr) Combinaison (a) d'inhibiteur d'adn topoisomerase et (b) d'inhibiteur de iap
WO2013071056A3 (fr) Polythérapie médicamenteuse pour le traitement de tumeurs solides
WO2008070010A3 (fr) Rétablissement après une attaque
ATE523200T1 (de) Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel
WO2008074833A3 (fr) Composés
GB0328180D0 (en) Combination
WO2007054725A3 (fr) Produit compose
WO2007062862A3 (fr) Utilisation d'inhibiteurs de la calmoduline pour traiter des troubles neurodegeneratifs
WO2007146375A3 (fr) Composés de pyrimido-dione-quinoléine hautement solubles et procédés de traitement du cancer
MXPA05004920A (es) Combinacion que comprende un inhibidor cdk y cisplatin.
MXPA05004917A (es) Combinacion que comprende docetaxel y un inhibidor cdk.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006808516

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006808516

Country of ref document: EP